Quarterly ResultAug 5, 2026, 05:00 PM
BioAge Labs Q2 Net Loss $26.1M; BGE-102 Phase 2 Progress
AI Summary
BioAge Labs reported a net loss of $26.1 million, or $0.58 per share, for the second quarter of 2026, compared to a net loss of $21.6 million, or $0.60 per share, in the same period last year. Research and development expenses increased to $24.4 million, primarily due to advancements in the BGE-102 program. The company announced the dosing of the first participant in its QUELL-CV Phase 2 trial for BGE-102 and plans to initiate the QUELL-DME Phase 1b/2a trial in mid-2026. BioAge Labs maintains a strong financial position with $381.3 million in cash, cash equivalents, and marketable securities, projected to fund operations through 2029.
Key Highlights
- Net loss for Q2 2026 was $26.1 million, compared to $21.6 million in Q2 2025.
- Net loss per share was $0.58 for Q2 2026, compared to $0.60 in Q2 2025.
- Research and development expenses increased to $24.4 million in Q2 2026 from $19.8 million in Q2 2025.
- Collaboration revenue was $2.4 million for both Q2 2026 and Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $381.3 million as of June 30, 2026.
- Company estimates existing cash will fund operations through 2029.
- First participant dosed in QUELL-CV Phase 2 trial for BGE-102 in June 2026, with topline data expected H2 2026.
- QUELL-DME Phase 1b/2a trial for BGE-102 in diabetic macular edema planned to initiate mid-2026, data anticipated mid-2027.
Price Impact
More from BIOA